The practical use of antibiotherapy is currently undergoing a change due to several factors, including the emergence of multi-resistant bacteria. Our studies with directed- spectrum drugs will allow us to offer new therapeutic regimens and therefore keep broad-spectrum antibiotics for infections where they remain the last effective ones. Moreover, when using directed-spectrum antibiotics, the bacterial ecology is also preserved.
Negaban® temocillin, a 6-α methoxy penicillin derivative (ß-lactam), has a sustained profile of susceptibility, more than a decade after its introduction into daily clinical practice.
Negaban® temocillin, a narrow spectrum directed towards gram-negative bacteria with a proven stability against most types of ß-lactamases, including ESBLs and AmpCs.
